IGF-ILR3

Descrição

IGF-1 LR3 (Long Arginine 3 Insulin-like Growth Factor-1) is a synthetic 83-amino-acid analog of insulin-like growth factor-1 (IGF-1) modified by substituting arginine for glutamic acid at position 3 and adding 13 extra amino acids at the N-terminus. These changes dramatically increase its half-life (20–30 hours vs. ~10–20 minutes for native IGF-1) and greatly reduce affinity for IGF-binding proteins (IGFBPs), allowing IGF-1 LR3 to remain biologically active much longer in circulation and tissues while exerting stronger anabolic and hypertrophic effects. By binding to IGF-1 receptors (and to a lesser extent insulin receptors), IGF-1 LR3 stimulates satellite cell proliferation and fusion (muscle hyperplasia), enhances protein synthesis, promotes nutrient uptake (glucose and amino acids), accelerates muscle repair after microtrauma or injury, increases muscle fiber size, and supports overall tissue growth and regeneration with minimal systemic insulin-like side effects compared to full hGH therapy. Preclinical studies and extensive anecdotal evidence from bodybuilding, physique enhancement, and regenerative medicine communities highlight IGF-1 LR3’s ability to produce site-specific muscle growth (often injected bilaterally into lagging muscle groups), faster recovery from intense training, improved muscle fullness and vascularity, enhanced lean mass gains, and better nutrient partitioning during bulking or recomp phases. Typical research protocols involve subcutaneous or intramuscular injection (commonly 20–100 mcg per muscle group, often 40–80 mcg total daily, split or single dose) immediately post-workout or pre-bed, 3–5 days per week, with cycles usually limited to 4–6 weeks followed by equal time off to avoid potential receptor downregulation or diminishing returns. Many users report noticeable localized hypertrophy, reduced recovery time, and superior “pump” effects within the first 1–4 weeks when combined with progressive overload training, high-protein nutrition, and adequate rest. While highly regarded for its targeted anabolic and regenerative profile, IGF-1 LR3 is not FDA-approved for any therapeutic, performance enhancement, anti-aging, or medical use as of 2026—it remains an investigational research peptide with evidence derived primarily from in vitro studies, animal models, and widespread anecdotal/user experiences rather than large-scale human clinical trials. Reported side effects from user reports are generally mild (injection-site irritation, temporary hypoglycemia-like symptoms [lightheadedness, shakiness], localized swelling or redness, fatigue, or joint discomfort), but potential risks include significant hypoglycemia (due to enhanced glucose uptake), possible abnormal cell growth promotion in long-term use, water retention, or unknown long-term effects on insulin sensitivity or organ systems. It is prohibited by WADA for athletes and should never be used without supervision from a qualified healthcare provider experienced in peptides, as self-administration carries risks of contamination from unregulated sources, improper dosing, adverse reactions (including severe hypoglycemia), or legal issues. Prioritize evidence-based muscle-building and recovery strategies—progressive overload training, optimal nutrition, sleep, and approved therapies—over unapproved research compounds. Consult a professional to assess suitability, and stay informed on emerging research or regulatory developments. IGF-1 LR3 is not a substitute for proven medical treatments, rehabilitation, or lifestyle interventions.